NCT07247162 · RECORDATI GROUP
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
(LINC CARE)
What this study is about
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia.
View original scientific description
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
Interventions
DRUG
Osilodrostat
Osilodrostat tablets 1 mg and 5 mg for oral useOsilodrostat tablets 1 mg and 5 mg for oral use.During the 18-week titration phase, the dose of the medication will be titrated every 3 weeks based on the cortisolaemic and clinical response to treatment. An independent endocrinologist titration committee will be applied to provide recommendations on dose-titration based on biochemical and clinical response. At the end of the 18-week dose titration phase, participants will enter a 12-week dose maintenance phase, which is also blinded. They will continue with the dose they were receiving at the end of the dose titration phase, unless there is a need to down-titrate or to stop the study medication for safety purposes.
DRUG
Placebo
matching placebo
Primary outcome measures
To evaluate the efficacy of osilodrostat on the proportion of participants with normalization of urinary-free cortisol (UFC)
Time frame: 30 weeks
Normalization status for each participant at Week 30 of treatment with osilodrostat or placebo, based on the mean of UFC concentrations from two 24-hour urine collections, with normalization defined as ≤1× the upper limit of normal (ULN).
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Male or female ≥ 18 years of age
- Able to provide and have provided signed written informed consent prior to study participation
- Diagnosis of endogenous Cushing's Syndrome
- mUFC values from two 24h urinary collections \> ULN and ≤ 2x ULN
- Participants with uncontrolled hypertension on stable doses of BP lowering medications (for at least 4 weeks); qualifying BP measurements by ABPM taken prior to randomisation defined as: Average of 24h ABPM SBP ≥ 135 or DBP ≥ 85 mmHg
- Participants under glucocorticoid replacement therapy can be recruited only if this therapy has been already stopped for at least seven days or 5 half-lives prior to screening, whichever was longer
- Not taking any drug therapy for CS. The following minimum periods without these medications need to be completed before baseline assessments:
- Steroidogenesis inhibitors (e.g. ketoconazole, metyrapone): 1 week
- Mifepristone: 3 weeks
- SC Pasireotide: 1 week
- Pasireotide LAR: 3 months
- Cabergoline: 4 weeks
- Able to take oral medication and be willing to comply with the requirements of the study
Exclusion criteria
- Previously treated with osilodrostat less than 12 weeks prior to start of screening
- Known hypersensitivity to osilodrostat
- Presence of any severe and/or uncontrolled medical condition or other conditions that could affect participation in the study
- Participants who are scheduled for a surgery to treat CS within 32 weeks of randomisation to the study drug
- Presence of a known "long term" history of both hypertension and diabetes (defined as both hypertension and diabetes diagnosed \>10 years prior to the initial diagnosis of endogenous CS)
- History of cyclic CS with fluctuating clinical manifestations
- Participants with pseudo-CS
- Participants with compression of the optic chiasm due to a macroadenoma or participants at high risk of compression of the optic chiasm (tumour within 2 mm of optic chiasm)
- Participants who have undergone pituitary or adrenal surgery for Cushing's syndrome within 3 months prior to screening.
- Pituitary radiation therapy within 3 years of screening
- Ectopic ACTH syndrome or adrenocortical carcinoma with a life expectancy of \<3 years or receiving chemotherapy
- Having received prior mitotane treatment
- Participants who are shift workers or have conditions that can affect the measurement of late-night salivary cortisol (LNSC) or the LDDST
- Poorly controlled diabetes mellitus with a baseline HbA1c \> 10.5%. Participants receiving glucose lowering medications must be on stable doses for at least 4 weeks prior screening.
- Participants who are hypothyroid and not on adequate replacement therapy
- History of major surgery/surgical therapy for any cause within 4 weeks before entering the study. Participants should have recovered from the surgery and be in good clinical condition before entering the study
- Presence of bradycardia and/or QT-related exclusion criteria
- Total bilirubin \> 1.5 x ULN and ALT or AST \> 3 x ULN
- Participation in any clinical investigation within 4 weeks prior to screening or longer if required by local regulation (Use of an investigational drug within 4 weeks prior to dosing)
- Occurrence of any significant acute illness within 3 weeks prior to dosing/randomisation
- Female participants who are pregnant, intending to become pregnant or breastfeed during the study or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
- Women of childbearing potential (WOCBP) who are unwilling to use highly effective contraception methods
- Potentially unreliable or vulnerable participants (e.g. person kept in detention) and those judged by the Investigator to be unsuitable for the study.
Where
- Jacksonville, Florida
- Canton, Ohio
- Weslaco, Texas
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 2, 2026 · Source of record for eligibility and locations